| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | -0.0089 | 0.9 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.0024 | 0.9 |